Skip to main content
Erschienen in: Molecular Diagnosis & Therapy 1/2018

01.02.2018 | Review Article

Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes

verfasst von: Maryam Zarkesh, Azita Zadeh-Vakili, Fereidoun Azizi, Forough Foroughi, Maziar Mohammad Akhavan, Mehdi Hedayati

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Thyroid carcinoma (TC) is the most frequent malignant neoplasm of the endocrine system. Molecular methods for diagnosis of invasive thyroid disease can be effectively adopted. Epigenetic factors play an important role in the diversity patterns of gene expression and the phenotypic and biological characteristics of TC subtypes. We aimed to review epigenetic changes in the main subtypes of TC, along with a presentation of the methods that have examined these changes, and active clinical trials for the treatment of advanced TCs targeting epigenetic changes. A literature analysis was performed in MEDLINE using PubMed, Elsevier, and Google Scholar for studies published up to 2016, using the keywords: “Epigenetic alterations” OR “Epigenetic changes”, “thyroid cancers”, “papillary thyroid cancer”, “medullary thyroid cancer”, “follicular thyroid cancer”, and “anaplastic thyroid cancer”, which resulted in 310 articles in English. All related abstracts were reviewed and studies were included that were published in English, had available full text, and determined the details of the methods and materials associated with the epigenetic patterns of TC and its subtypes (100 articles). Analysis of epigenetic alterations in TC subtypes helps to identify pathogenesis and can play an important role in the classification and diagnosis of tumors. Epigenetic mechanisms, especially aberrant methylation of DNA and microRNAs (miRs), are likely to play an important role in thyroid tumorigenesis. Further studies are required to elucidate the role of histone modification mechanisms in TC development.
Literatur
4.
Zurück zum Zitat Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161–70.PubMedCrossRef Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161–70.PubMedCrossRef
5.
Zurück zum Zitat Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014;24(8):1256–66.PubMedPubMedCentralCrossRef Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014;24(8):1256–66.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Şahpaz A, Önal B, Yeşilyurt A, Han Ü, Delibaşı T. BRAFV600E mutation, RET/PTC1 and PAX8-PPAR gamma rearrangements in follicular epithelium derived thyroid lesions-institutional experience and literature review. Balkan Med J. 2015;32(2):156–66.PubMedPubMedCentralCrossRef Şahpaz A, Önal B, Yeşilyurt A, Han Ü, Delibaşı T. BRAFV600E mutation, RET/PTC1 and PAX8-PPAR gamma rearrangements in follicular epithelium derived thyroid lesions-institutional experience and literature review. Balkan Med J. 2015;32(2):156–66.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–26.PubMedCrossRef Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–26.PubMedCrossRef
8.
Zurück zum Zitat Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–116.PubMedPubMedCentralCrossRef Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–116.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef
11.
Zurück zum Zitat Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119(10):2322–9.PubMedCrossRef Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119(10):2322–9.PubMedCrossRef
12.
13.
Zurück zum Zitat Zhao Z, Herman JG, Brock MV, Sheng J, Zhang M, Liu B, et al. Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling. PloS One. 2014. doi:10.1371/journal.pone.0112336. Zhao Z, Herman JG, Brock MV, Sheng J, Zhang M, Liu B, et al. Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling. PloS One. 2014. doi:10.​1371/​journal.​pone.​0112336.
14.
Zurück zum Zitat Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, et al. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab. 2011;96(3):E554–65. doi:10.1210/jc.2010-1800.PubMedCrossRef Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, et al. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab. 2011;96(3):E554–65. doi:10.​1210/​jc.​2010-1800.PubMedCrossRef
17.
Zurück zum Zitat Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013;98(7):2811–21. doi:10.1210/jc.2012-3566.PubMedCrossRef Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013;98(7):2811–21. doi:10.​1210/​jc.​2012-3566.PubMedCrossRef
18.
Zurück zum Zitat Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62(13):3698–701.PubMed Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62(13):3698–701.PubMed
19.
20.
Zurück zum Zitat Xing M, Tokumaru Y, Wu G, Westra WB, Ladenson PW, Sidransky D. Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Res. 2003;63(9):2312–5.PubMed Xing M, Tokumaru Y, Wu G, Westra WB, Ladenson PW, Sidransky D. Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Res. 2003;63(9):2312–5.PubMed
21.
Zurück zum Zitat Mancikova V, Buj R, Castelblanco E, Inglada-Pérez L, Diez A, Cubas AA, et al. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. Int J Cancer. 2014;135(3):598–610.PubMedCrossRef Mancikova V, Buj R, Castelblanco E, Inglada-Pérez L, Diez A, Cubas AA, et al. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. Int J Cancer. 2014;135(3):598–610.PubMedCrossRef
22.
Zurück zum Zitat Lee EK, Chung KW, Yang SK, Park MJ, Min HS, Kim SW, et al. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma. Anticancer Res. 2013;33(11):4833–9.PubMed Lee EK, Chung KW, Yang SK, Park MJ, Min HS, Kim SW, et al. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma. Anticancer Res. 2013;33(11):4833–9.PubMed
23.
Zurück zum Zitat Mete O, Asa SL. Endocrine pathology [with online resource]. Cambridge: Cambridge University Press; 2016. Mete O, Asa SL. Endocrine pathology [with online resource]. Cambridge: Cambridge University Press; 2016.
26.
Zurück zum Zitat Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, et al. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab. 2014;99(2):E329–37.PubMedCrossRef Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, et al. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab. 2014;99(2):E329–37.PubMedCrossRef
27.
Zurück zum Zitat Ishida E, Nakamura M, Shimada K, Higuchi T, Takatsu K, Yane K, et al. DNA hypermethylation status of multiple genes in papillary thyroid carcinomas. Pathobiology. 2007;74(6):344–52.PubMedCrossRef Ishida E, Nakamura M, Shimada K, Higuchi T, Takatsu K, Yane K, et al. DNA hypermethylation status of multiple genes in papillary thyroid carcinomas. Pathobiology. 2007;74(6):344–52.PubMedCrossRef
28.
Zurück zum Zitat Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, Bonnetaud C, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18(6):711–9. doi:10.1530/ERC-10-0257.PubMedCrossRef Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, Bonnetaud C, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18(6):711–9. doi:10.​1530/​ERC-10-0257.PubMedCrossRef
29.
Zurück zum Zitat Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 2008;68(16):6770–8.PubMedCrossRef Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 2008;68(16):6770–8.PubMedCrossRef
30.
Zurück zum Zitat Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, et al. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res. 2009;69(17):7079–87.PubMedCrossRef Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, et al. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res. 2009;69(17):7079–87.PubMedCrossRef
31.
Zurück zum Zitat Zhang Z, Liu D, Murugan AK, Liu Z, Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014;21(2):161–73.PubMedPubMedCentralCrossRef Zhang Z, Liu D, Murugan AK, Liu Z, Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014;21(2):161–73.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14(3):791–8. doi:10.1677/ERC-07-0129.PubMedCrossRef Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14(3):791–8. doi:10.​1677/​ERC-07-0129.PubMedCrossRef
33.
34.
Zurück zum Zitat Li D, Jian W, Wei C, Song H, Gu Y, Luo Y, et al. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol. 2014;7(11):7672–80.PubMedPubMedCentral Li D, Jian W, Wei C, Song H, Gu Y, Luo Y, et al. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol. 2014;7(11):7672–80.PubMedPubMedCentral
36.
Zurück zum Zitat Cahill S, Smyth P, Denning K, Flavin R, Li J, Potratz A, et al. Effect of BRAF V600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer. 2007;6(1):1.CrossRef Cahill S, Smyth P, Denning K, Flavin R, Li J, Potratz A, et al. Effect of BRAF V600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer. 2007;6(1):1.CrossRef
37.
Zurück zum Zitat Song HM, Luo Y, Li DF, Wei CK, Hua KY, Song JL, et al. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Int J Clin Exp Pathol. 2015;8(9):9889–900.PubMedPubMedCentral Song HM, Luo Y, Li DF, Wei CK, Hua KY, Song JL, et al. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Int J Clin Exp Pathol. 2015;8(9):9889–900.PubMedPubMedCentral
38.
Zurück zum Zitat Gu Y, Li D, Luo Q, Wei C, Song H, Hua K, et al. MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6. Int J Clin Exp Med. 2015;8(6):8590–8.PubMedPubMedCentral Gu Y, Li D, Luo Q, Wei C, Song H, Hua K, et al. MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6. Int J Clin Exp Med. 2015;8(6):8590–8.PubMedPubMedCentral
39.
Zurück zum Zitat Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18(7):2035–41. doi:10.1245/s10434-011-1733-0.PubMedCrossRef Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18(7):2035–41. doi:10.​1245/​s10434-011-1733-0.PubMedCrossRef
42.
44.
Zurück zum Zitat Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg. 2007;31(7):1417–24. doi:10.1007/s00268-007-9095-2.PubMedCrossRef Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg. 2007;31(7):1417–24. doi:10.​1007/​s00268-007-9095-2.PubMedCrossRef
45.
Zurück zum Zitat Randolph GW. Surgery of the thyroid and parathyroid glands. Expert consult premium edition—enhanced online features. 2nd ed. Philadelphia: Elsevier Health Sciences; 2012. Randolph GW. Surgery of the thyroid and parathyroid glands. Expert consult premium edition—enhanced online features. 2nd ed. Philadelphia: Elsevier Health Sciences; 2012.
47.
Zurück zum Zitat Stephen JK, Chen KM, Merritt J, Chitale D, Divine G, Worsham MJ. Methylation markers for early detection and differentiation of follicular thyroid cancer subtypes. Cancer Clin Oncol. 2015;4(2):1–12. doi:10.5539/cco.v4n2p1.PubMedPubMedCentral Stephen JK, Chen KM, Merritt J, Chitale D, Divine G, Worsham MJ. Methylation markers for early detection and differentiation of follicular thyroid cancer subtypes. Cancer Clin Oncol. 2015;4(2):1–12. doi:10.​5539/​cco.​v4n2p1.PubMedPubMedCentral
49.
Zurück zum Zitat Joseph B, Ji M, Liu D, Hou P, Xing MM. Lack of mutations in the thyroid hormone receptor (TR) α and β genes but frequent hypermethylation of the TRβ gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007;92(12):4766–70. doi:10.1210/jc.2007-0812.PubMedCrossRef Joseph B, Ji M, Liu D, Hou P, Xing MM. Lack of mutations in the thyroid hormone receptor (TR) α and β genes but frequent hypermethylation of the TRβ gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007;92(12):4766–70. doi:10.​1210/​jc.​2007-0812.PubMedCrossRef
50.
Zurück zum Zitat Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY. Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology. 2013;154(1):25–35. doi:10.1210/en.2012-1728.PubMedCrossRef Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY. Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology. 2013;154(1):25–35. doi:10.​1210/​en.​2012-1728.PubMedCrossRef
51.
Zurück zum Zitat Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors. Cancer Res. 2003;63(9):2316–21.PubMed Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors. Cancer Res. 2003;63(9):2316–21.PubMed
52.
Zurück zum Zitat Seligson DB, Horvath S, Shi T, Yu H. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262.PubMedCrossRef Seligson DB, Horvath S, Shi T, Yu H. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262.PubMedCrossRef
53.
Zurück zum Zitat Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174(5):1619–28.PubMedPubMedCentralCrossRef Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174(5):1619–28.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Colamaio M, Puca F, Ragozzino E, Gemei M, Decaussin-Petrucci M, Aiello C, et al. miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J Clin Endocrinol Metab. 2015;100(1):E59–69. doi:10.1210/jc.2014-2280.PubMedCrossRef Colamaio M, Puca F, Ragozzino E, Gemei M, Decaussin-Petrucci M, Aiello C, et al. miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J Clin Endocrinol Metab. 2015;100(1):E59–69. doi:10.​1210/​jc.​2014-2280.PubMedCrossRef
55.
57.
58.
59.
Zurück zum Zitat Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23(9):1269.PubMedCrossRef Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23(9):1269.PubMedCrossRef
60.
Zurück zum Zitat Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006;13(2):119.PubMedCrossRef Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006;13(2):119.PubMedCrossRef
61.
Zurück zum Zitat Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161(5):1549–56.PubMedPubMedCentralCrossRef Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161(5):1549–56.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187–95.PubMedCrossRef Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187–95.PubMedCrossRef
63.
Zurück zum Zitat Horn-Ross PL, Lichtensztajn DY, Clarke CA, Dosiou C, Oakley-Girvan I, Reynolds P, et al. Continued rapid increase in thyroid cancer incidence in california: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2014;23(6):1067–79.CrossRef Horn-Ross PL, Lichtensztajn DY, Clarke CA, Dosiou C, Oakley-Girvan I, Reynolds P, et al. Continued rapid increase in thyroid cancer incidence in california: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2014;23(6):1067–79.CrossRef
64.
Zurück zum Zitat Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, et al. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene. 2004;23(5):1117.PubMedCrossRef Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, et al. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene. 2004;23(5):1117.PubMedCrossRef
65.
Zurück zum Zitat Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052.PubMedPubMedCentralCrossRef Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV. Non-coding RNAs in thyroid cancer. Endocr Pathol. 2016;27(1):12–20.PubMedCrossRef Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV. Non-coding RNAs in thyroid cancer. Endocr Pathol. 2016;27(1):12–20.PubMedCrossRef
69.
Zurück zum Zitat Schwertheim S, Sheu SY, Worm K, Grabellus F, Schmid KW. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res. 2009;41(6):475–81. doi:10.1055/s-0029-1215593.PubMedCrossRef Schwertheim S, Sheu SY, Worm K, Grabellus F, Schmid KW. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res. 2009;41(6):475–81. doi:10.​1055/​s-0029-1215593.PubMedCrossRef
70.
Zurück zum Zitat Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol. 2014;52(2):181–9.PubMedPubMedCentralCrossRef Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol. 2014;52(2):181–9.PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440–7. doi:10.1002/cncr.23869.PubMedCrossRef Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440–7. doi:10.​1002/​cncr.​23869.PubMedCrossRef
75.
Zurück zum Zitat Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest. 2009;89(7):791–9. doi:10.1038/labinvest.2009.50.PubMedCrossRef Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest. 2009;89(7):791–9. doi:10.​1038/​labinvest.​2009.​50.PubMedCrossRef
76.
Zurück zum Zitat Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96(4):1029–38. doi:10.1210/jc.2010-1784.PubMedCrossRef Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96(4):1029–38. doi:10.​1210/​jc.​2010-1784.PubMedCrossRef
77.
Zurück zum Zitat Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene. 2010;29(1):105–16. doi:10.1038/onc.2009.306.PubMedCrossRef Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene. 2010;29(1):105–16. doi:10.​1038/​onc.​2009.​306.PubMedCrossRef
78.
Zurück zum Zitat Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2014. doi:10.1210/jc.2014-2803. Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2014. doi:10.​1210/​jc.​2014-2803.
82.
Zurück zum Zitat Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517–31. doi:10.1530/erc-14-0077.PubMedCrossRef Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517–31. doi:10.​1530/​erc-14-0077.PubMedCrossRef
85.
Zurück zum Zitat Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012;97(5):E710–8.PubMedCrossRef Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012;97(5):E710–8.PubMedCrossRef
88.
Zurück zum Zitat Nozhat Z, Hedayati M, Pourhassan H. Signaling pathways in medullary thyroid carcinoma: therapeutic implications. Int J Endocr Oncol. 2016;3(4):299–312.CrossRef Nozhat Z, Hedayati M, Pourhassan H. Signaling pathways in medullary thyroid carcinoma: therapeutic implications. Int J Endocr Oncol. 2016;3(4):299–312.CrossRef
89.
Zurück zum Zitat Nozhat Z, Hedayati M. PI3K/AKT pathway and its mediators in thyroid carcinomas. Mol Diagn Ther. 2016;20(1):13–26.PubMedCrossRef Nozhat Z, Hedayati M. PI3K/AKT pathway and its mediators in thyroid carcinomas. Mol Diagn Ther. 2016;20(1):13–26.PubMedCrossRef
90.
Zurück zum Zitat Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, Rezghi Barez S, Hoghooghi Rad L, Azizi F. Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res. 2011;2011:264248. doi:10.4061/2011/264248.PubMedPubMedCentral Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, Rezghi Barez S, Hoghooghi Rad L, Azizi F. Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res. 2011;2011:264248. doi:10.​4061/​2011/​264248.PubMedPubMedCentral
91.
Zurück zum Zitat Alvandi E, Akrami SM, Chiani M, Hedayati M, Nayer BN, Tehrani MR, et al. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid. 2011;21(4):373–82. doi:10.1089/thy.2010.0267.PubMedCrossRef Alvandi E, Akrami SM, Chiani M, Hedayati M, Nayer BN, Tehrani MR, et al. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid. 2011;21(4):373–82. doi:10.​1089/​thy.​2010.​0267.PubMedCrossRef
92.
Zurück zum Zitat Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malays. 2006;61(5):564–9. Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malays. 2006;61(5):564–9.
93.
94.
Zurück zum Zitat Hedayati M, Zarif Yeganeh M, Daneshpour M, Delbarpour Ahmadi A, Azizi F. Frequent germ line mutations in RET proto-oncogene exons 10 and 11 in hereditary medullary thyroid carcinomas of Iranian patients. Kowsar Med J. 2010;15(1):17–21. Hedayati M, Zarif Yeganeh M, Daneshpour M, Delbarpour Ahmadi A, Azizi F. Frequent germ line mutations in RET proto-oncogene exons 10 and 11 in hereditary medullary thyroid carcinomas of Iranian patients. Kowsar Med J. 2010;15(1):17–21.
95.
Zurück zum Zitat Yeganeh MZ, Sheikholeslami S, Hedayati M. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pac J Cancer Prev. 2015;16(6):2107–17.PubMedCrossRef Yeganeh MZ, Sheikholeslami S, Hedayati M. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pac J Cancer Prev. 2015;16(6):2107–17.PubMedCrossRef
96.
Zurück zum Zitat Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid. 2006;16(7):633–42.PubMedCrossRef Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid. 2006;16(7):633–42.PubMedCrossRef
97.
Zurück zum Zitat Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, et al. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell Endocrinol. 2014;392(1–2):8–13. doi:10.1016/j.mce.2014.04.016.PubMedCrossRef Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, et al. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell Endocrinol. 2014;392(1–2):8–13. doi:10.​1016/​j.​mce.​2014.​04.​016.PubMedCrossRef
98.
Zurück zum Zitat Hudson J, Duncavage E, Tamburrino A, Salerno P, Xi L, Raffeld M, et al. Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 2013;95(1):62–7.PubMedPubMedCentralCrossRef Hudson J, Duncavage E, Tamburrino A, Salerno P, Xi L, Raffeld M, et al. Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 2013;95(1):62–7.PubMedPubMedCentralCrossRef
102.
Zurück zum Zitat Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3(1):5.PubMedPubMedCentralCrossRef Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3(1):5.PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27(32):5459–68.PubMedCrossRef Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27(32):5459–68.PubMedCrossRef
104.
Zurück zum Zitat Zarkesh M, Taghaddosi M, Azizi F, Zadeh-Vakili A, Hedayati M. Importance of epigenetic changes in the thyroid cancer incidence and their therapeutic applications. Modares J Med Sci Pathobiol. 2014;17(3):1–21. Zarkesh M, Taghaddosi M, Azizi F, Zadeh-Vakili A, Hedayati M. Importance of epigenetic changes in the thyroid cancer incidence and their therapeutic applications. Modares J Med Sci Pathobiol. 2014;17(3):1–21.
106.
Zurück zum Zitat Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(1):164–70. doi:10.1210/jc.2008-1631.PubMedCrossRef Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(1):164–70. doi:10.​1210/​jc.​2008-1631.PubMedCrossRef
107.
Zurück zum Zitat Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer. 2012;130(3):694–704.PubMedCrossRef Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer. 2012;130(3):694–704.PubMedCrossRef
109.
Zurück zum Zitat Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969–78.PubMedPubMedCentralCrossRef Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969–78.PubMedPubMedCentralCrossRef
110.
Zurück zum Zitat Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34(3):206–22.PubMedCrossRef Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34(3):206–22.PubMedCrossRef
111.
Zurück zum Zitat Nilubol N, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, et al. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. Clin Endocrinol (Oxf). 2017;86(1):128–33. doi:10.1111/cen.13154.CrossRef Nilubol N, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, et al. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. Clin Endocrinol (Oxf). 2017;86(1):128–33. doi:10.​1111/​cen.​13154.CrossRef
114.
115.
Zurück zum Zitat Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–16.PubMedCrossRef Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–16.PubMedCrossRef
116.
Zurück zum Zitat Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007;92(6):2387–90.PubMedCrossRef Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007;92(6):2387–90.PubMedCrossRef
117.
Zurück zum Zitat Zhang B, Liu S, Zhang Z, Wei J, Qu Y, Wu K, et al. Analysis of BRAFV600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies. Diagn Pathol. 2014. doi:10.1186/1746-1596-9-45. Zhang B, Liu S, Zhang Z, Wei J, Qu Y, Wu K, et al. Analysis of BRAFV600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies. Diagn Pathol. 2014. doi:10.​1186/​1746-1596-9-45.
119.
120.
Zurück zum Zitat Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Investig. 2005;115(1):94–101.PubMedPubMedCentralCrossRef Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Investig. 2005;115(1):94–101.PubMedPubMedCentralCrossRef
Metadaten
Titel
Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes
verfasst von
Maryam Zarkesh
Azita Zadeh-Vakili
Fereidoun Azizi
Forough Foroughi
Maziar Mohammad Akhavan
Mehdi Hedayati
Publikationsdatum
01.02.2018
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 1/2018
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-017-0303-y

Weitere Artikel der Ausgabe 1/2018

Molecular Diagnosis & Therapy 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.